Wedbush Analysts Boost Earnings Estimates for Regulus Therapeutics Inc. (NASDAQ:RGLS)

Regulus Therapeutics Inc. (NASDAQ:RGLS) – Equities researchers at Wedbush boosted their Q3 2017 EPS estimates for shares of Regulus Therapeutics in a research note issued to investors on Wednesday. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings of ($0.10) per share for the quarter, up from their prior forecast of ($0.20). Wedbush currently has a “Ourperform” rating and a $6.00 price target on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q4 2017 earnings at ($0.12) EPS, FY2017 earnings at ($0.66) EPS, Q1 2018 earnings at ($0.12) EPS, Q2 2018 earnings at ($0.13) EPS, Q3 2018 earnings at ($0.14) EPS, Q4 2018 earnings at ($0.14) EPS and FY2018 earnings at ($0.54) EPS.

WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/19/wedbush-analysts-boost-earnings-estimates-for-regulus-therapeutics-inc-nasdaqrgls-updated-updated.html.

Other equities research analysts have also recently issued reports about the stock. Chardan Capital decreased their price target on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a report on Tuesday, June 13th. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Wednesday, July 12th. BMO Capital Markets restated a “hold” rating on shares of Regulus Therapeutics in a report on Monday, May 15th. Finally, ValuEngine cut shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. Regulus Therapeutics currently has an average rating of “Hold” and an average target price of $3.92.

Regulus Therapeutics (NASDAQ RGLS) opened at 1.05 on Monday. Regulus Therapeutics has a 52-week low of $0.86 and a 52-week high of $3.92. The firm has a 50-day moving average price of $1.01 and a 200 day moving average price of $1.36. The stock’s market capitalization is $55.84 million.

Several hedge funds and other institutional investors have recently made changes to their positions in RGLS. Tudor Investment Corp ET AL raised its position in shares of Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 61,373 shares in the last quarter. South Dakota Investment Council raised its position in shares of Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock worth $2,190,000 after buying an additional 186,130 shares in the last quarter. Wedbush Securities Inc. raised its position in shares of Regulus Therapeutics by 106.8% in the first quarter. Wedbush Securities Inc. now owns 180,921 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 93,420 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 93,295 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in shares of Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 9,804 shares in the last quarter. 38.53% of the stock is owned by institutional investors and hedge funds.

In related news, insider Joseph P. Hagan acquired 219,780 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was acquired at an average price of $0.91 per share, with a total value of $199,999.80. Following the completion of the transaction, the insider now owns 241,297 shares of the company’s stock, valued at $219,580.27. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William H. Rastetter acquired 274,725 shares of the business’s stock in a transaction dated Tuesday, July 25th. The shares were bought at an average cost of $0.91 per share, with a total value of $249,999.75. The disclosure for this purchase can be found here. Insiders have acquired 549,450 shares of company stock valued at $500,000 over the last 90 days. Corporate insiders own 4.80% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

What are top analysts saying about Regulus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regulus Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit